JAZZ · NASDAQ
Jazz Pharmaceuticals (JAZZ) Stock Price & Fundamentals
Jazz Pharmaceuticals (JAZZ) closed at $666.67 on Oct 9, 2026, down 0.14% from the previous close of $667.58.
Share price, past year
1Y +19.81%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $666.67 |
| Sep 30, 2026 | $668.63 |
| Aug 31, 2026 | $638.31 |
| Jul 31, 2026 | $670.08 |
| Jun 30, 2026 | $676.67 |
| May 29, 2026 | $695.65 |
| Apr 30, 2026 | $636.33 |
| Mar 31, 2026 | $612.70 |
| Feb 27, 2026 | $552.54 |
| Jan 30, 2026 | $592.13 |
| Dec 31, 2025 | $587.36 |
| Nov 28, 2025 | $560.75 |
| Oct 31, 2025 | $552.89 |
Key statistics
- Market cap
- $40.96B
- P/E (TTM)
- 45.6
- EPS (TTM)
- $14.63
- Revenue (TTM)
- $4.60B
- Net income (TTM)
- $940.75M
- Shares outstanding
- 61.4M
- Dividend yield
- —
- 52-week range
- $548.05 – $705.70
Jazz Pharmaceuticals's market cap is $40.96B, based on a share price of $666.67 and 61.4M shares outstanding as of Dec 31, 2025.
Financials
Jazz Pharmaceuticals reported revenue of $4.27B for fiscal 2025, up 4.88% from fiscal 2024.
Jazz Pharmaceuticals reported a net loss of $356.15M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 10 years shown.
Jazz Pharmaceuticals's fiscal 2025 net loss was its first in at least 3 years.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $4.27B | +4.9% | −$356.15M | −8.4% | −$5.84 | $1.30B |
| FY2024ended Dec 31, 2024 | $4.07B | +6.1% | $560.12M | 13.8% | $8.65 | $1.36B |
| FY2023ended Dec 31, 2023 | $3.83B | +4.8% | $414.83M | 10.8% | $6.10 | $1.07B |
| FY2022ended Dec 31, 2022 | $3.66B | +18.3% | −$224.06M | −6.1% | −$3.58 | $1.24B |
| FY2021ended Dec 31, 2021 | $3.09B | +30.9% | −$329.67M | −10.7% | −$5.52 | $750.87M |
| FY2020ended Dec 31, 2020 | $2.36B | +9.3% | $238.62M | 10.1% | $4.22 | $884.64M |
| FY2019ended Dec 31, 2019 | $2.16B | +14.3% | $523.37M | 24.2% | $9.09 | $736.27M |
| FY2018ended Dec 31, 2018 | $1.89B | +16.8% | $447.10M | 23.6% | $7.30 | $778.53M |
| FY2017ended Dec 31, 2017 | $1.62B | +8.8% | $487.85M | 30.1% | $7.96 | — |
| FY2016ended Dec 31, 2016 | $1.49B | — | $396.83M | 26.7% | $6.41 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $1.21B | $192.80M | $2.78 |
| Q1 FY2026ended Mar 31, 2026 | $1.07B | $293.10M | $4.43 |
| Q4 FY2025ended Dec 31, 2025 | $1.20B | $203.44M | $3.34 |
| Q3 FY2025ended Sep 30, 2025 | $1.13B | $251.41M | $4.08 |
| Q2 FY2025ended Jun 30, 2025 | $1.05B | −$718.50M | −$11.74 |
| Q1 FY2025ended Mar 31, 2025 | $897.80M | −$92.50M | −$1.52 |
| Q4 FY2024ended Dec 31, 2024 | $1.09B | $191.12M | $2.97 |
| Q3 FY2024ended Sep 30, 2024 | $1.05B | $215.06M | $3.42 |
Company profile
- Name
- Jazz Pharmaceuticals plc
- Ticker
- JAZZ
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin, D04 E5W7
- Incorporated in
- L2
- Fiscal year ends
- December
- SEC CIK
- 0001232524
Recent SEC filings
- Sep 23, 2026
- Sep 15, 2026
- Aug 31, 2026
- Aug 25, 2026
- Aug 10, 2026
- Aug 10, 2026
- Aug 3, 2026
- Aug 3, 2026
Frequently asked questions
What is Jazz Pharmaceuticals's stock price?
Jazz Pharmaceuticals (JAZZ) closed at $666.67 on Oct 9, 2026, down 0.14% from the previous close of $667.58.
What is Jazz Pharmaceuticals's market cap?
Jazz Pharmaceuticals's market cap is $40.96B, based on a share price of $666.67 and 61.4M shares outstanding as of Dec 31, 2025.
How much revenue does Jazz Pharmaceuticals make?
Jazz Pharmaceuticals reported revenue of $4.27B for fiscal 2025, up 4.88% from fiscal 2024.
What is JAZZ's P/E ratio?
Jazz Pharmaceuticals's price-to-earnings ratio is 45.6, based on trailing twelve-month diluted EPS of $14.63.
Does Jazz Pharmaceuticals pay a dividend?
Jazz Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Jazz Pharmaceuticals plc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures